ArticleSignal transduction and targeted therapy2023

Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.

Chuan Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.